Proscia, a provider of digital and computational pathology solutions, has released study results on new technology that leverages artificial intelligence (AI) to automatically detect melanoma, the deadliest form of skin cancer, with a high degree of accuracy.
The study, conducted at Thomas Jefferson University and the University of Florida, demonstrated the real-world performance of the AI on an uncurated set of 1,422 sequential skin biopsies. The technology correctly identified invasive melanoma and melanoma in situ with a sensitivity of 93% and a specificity of 91%. It also classified basal cell carcinoma and squamous cell carcinoma with an AUC of .97 and .95, respectively, accounting for a combined 97% of all skin cancers. This study validated the results of a multi-site retrospective study of 12,784 images, which will be presented during the Computational Challenges in Digital Pathology Workshop at the 2021 International Conference on Computer Vision.
Dr. Kiran Motaparthi, director of Dermatopathology and clinical associate professor of Dermatology at the University of Florida, said: “The performance of Proscia’s technology in detecting melanoma and other malignant skin diseases is impressive. This is an exciting development as pathologists increasingly look to unlock new sources of value from artificial intelligence."
In addition to the prospective and retrospective studies, Proscia is conducting additional research to demonstrate the potential benefits of AI in dermatopathology, including:
- Delivering faster results to patients. AI that automatically identifies melanoma alerts the pathologist to these high-risk cases, flagging them for earlier diagnosis. As the volume of skin biopsies continues to rise, this detection could help to ensure that patients with the most clinically impactful diagnoses are prioritised so that they can begin treatment sooner.
- Driving consistency in the diagnosis of difficult melanoma cases. Melanoma is among the most challenging diseases to diagnose, leading to interobserver variability among pathologists. The ability of AI to distinguish melanoma from benign mimickers could serve as an adjunctive aid to the pathologist, increasing diagnostic accuracy and improving patient outcomes.
- Optimising laboratory productivity to enhance profitability. More than 15 million skin biopsies are taken annually in the United States, each of which may display one of hundreds of diagnoses. AI that classifies and distinguishes melanoma and non-melanoma skin cancer could enable laboratories to optimise case distribution among specialists and non-specialists, resulting in efficiency gains that make it possible to process more case volume and partially overcome the impact of declining reimbursements.
Julianna Ianni, Ph.D., Proscia's vice president of AI Research & Development, said: "Proscia’s technology represents a significant advancement in our work on skin pathology. Our AI not only identifies melanoma, a difficult diagnosis, but also accounts for the high degree of variation in disease to push the boundaries of deep learning in medicine. In doing so, it holds great promise to help pathologists deliver faster, more consistent diagnoses and improve patient outcomes."
The AI validated in the study expands upon the technology that powers Proscia’s DermAI application. Available on the Concentriq digital pathology platform, DermAI provides an AI-based classification for every skin case to drive efficiency and quality gains. The application’s performance was demonstrated in one of pathology’s most comprehensive studies to date, and it continues to be validated and deployed as part of Proscia's ongoing work in AI. The company is also collaborating with leading academic and commercial laboratories, including LabPON, Johns Hopkins School of Medicine, Unilabs, University Medical Center Utrecht, and University of California, San Francisco, to accelerate the adoption of AI in pathology.
